Company attributes
Other attributes
Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.
Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.
In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”.
Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.
On July 9, 2015 Eligo Bioscience completed their seed funding round with €2.6M from Seventure Partners (lead investor) and Worldwide Innovation Challenge.
On September 26, 2017 Eligo Bioscience completed their series A funding round with $20million in funding from Seventure Partners and Khosla Ventures.
